ERBB2 and breast cancer: Regarding breast cancer subtype, 176 (36.6%) patients had the luminal A subtype, 208 (43.2%) had the luminal B subtype, 37 (7.7%) had the HER2-enriched subtype, and 60 (12.5%) had triple-negative breast cancer.